Arbios Systems to Present at the Rodman & Renshaw 8th Annual Healthcare Conference
November 02 2006 - 9:00AM
PR Newswire (US)
WALTHAM, Mass., Nov. 2 /PRNewswire-FirstCall/ -- Arbios Systems,
Inc. (OTC:ABOS) (BULLETIN BOARD: ABOS) , a company developing
proprietary medical devices and cell-based therapies for the
millions of patients each year who experience or are at risk for
life-threatening episodes of liver failure, today announced that
Walter C. Ogier, President and Chief Executive Officer, will
present a corporate update at the Rodman & Renshaw 8th Annual
Healthcare Conference at The Palace Hotel in New York City. As part
of his presentation, Mr. Ogier will review the recently reported
data from the first five patients treated with the SEPET(TM) Liver
Assist Device in the Company's ongoing feasibility IDE clinical
trial as well as preliminary results of treatment of additional
patients in the clinical trial. Mr. Ogier is scheduled to speak on
Wednesday, November 8, 2006 at 11:20AM Eastern Time in the Holmes I
room. The Company's presentation at the conference will be
available via web cast by accessing
http://www.wsw.com/webcast/rrshq10/abos, or through the Arbios
website at http://www.arbios.com/. About Arbios Systems Arbios
Systems, Inc. is developing proprietary medical devices and cell-
based therapies to enhance the survival of millions of patients
each year who experience, or are at risk for, life-threatening
episodes of liver failure. The Arbios product candidate portfolio
includes the SEPET(TM) Liver Assist Device, a novel blood
purification therapy that provides enhanced "liver dialysis," and
the HepatAssist(TM) Cell-Based Liver Support System, a
bioartificial liver that combines blood detoxification with liver
cell therapy to replace whole liver function in patients with the
most severe forms of liver failure. For more information on the
Company, please visit http://www.arbios.com/. This press release
contains forward-looking statements that involve risks and
uncertainties that could cause actual events or results to differ
materially from the events or results described in the
forward-looking statements, including risks or uncertainties
related to future markets for the Company's products and goals and
objectives of the Company's product and clinical development
programs.. These statements represent the judgment of Arbios'
management as of this date and are subject to risks and
uncertainties that could materially affect the Company. Arbios
cautions investors that there can be no assurance that actual
results or business conditions will not differ materially from
those projected or suggested in such forward-looking statements.
Please refer to our Annual Report on Form 10-KSB for the fiscal
year ended December 31, 2005 for a description of risks that may
affect our results or business conditions. The Company does not
undertake any obligation to publicly release the result of any
revisions to such forward-looking statements that may be made to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events except as required by law.
SEPET(TM) and HepatAssist(TM) are trademarks of Arbios Systems,
Inc. DATASOURCE: Arbios Systems, Inc. CONTACT: Contact at Arbios:
Walter C. Ogier, +1-781-839-7293, ; or Contact at Rx Communications
Group: Paula Schwartz, Investors, +1-917-322-2216, or Pat Garrison,
Media, +1-917-322-2567; or at MacDougall Biomedical Communications:
Doug MacDougall, +1-508-647-0209 Web site: http://www.arbios.com/
http://www.wsw.com/webcast/rrshq10/abos
Copyright